Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics

Zacks
Открыть на Zacks
Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics

For the quarter ended September 2026, Qiagen (QGEN) reported revenue of $547.87 million, up 2.9% over the same period last year. EPS came in at $0.65, compared to $0.64 in the year-ago quarter.

The reported revenue represents a surprise of +1.56% over the Zacks Consensus Estimate of $539.44 million. With the consensus EPS estimate being $0.63, the EPS surprise was +3.18%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Qiagen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Sales by Product Groups- Diagnostic solutions- QIAstat-Dx: $35 million versus the four-analyst average estimate of $36 million. The reported number represents a year-over-year change of +9.4%. Sales by Product Groups- Diagnostic solutions- QuantiFERON: $136 million versus $130.69 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a 0% change. Sales by Product Groups- Other: $14 million compared to the $12.39 million average estimate based on three analysts. The reported number represents a change of -22.2% year over year. Sales by Product Groups- PCR / Nucleic acid amplification: $71 million versus $71.88 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -5.3% change. Sales by Product Groups- Genomics / NGS: $66 million compared to the $61.18 million average estimate based on three analysts. The reported number represents a change of +8.2% year over year. Sales by Product Groups- Diagnostic solutions: $209 million versus $204.63 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a 0% change. Sales by Product Groups- Sample technologies: $187 million compared to the $185.09 million average estimate based on three analysts. The reported number represents a change of +10% year over year. Sales by Product Groups- Diagnostic solutions- Other: $38 million versus $41.46 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -7.3% change.

View all Key Company Metrics for Qiagen here>>>

Shares of Qiagen have returned +10.4% over the past month versus the Zacks S&P 500 composite's -2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
QIAGEN N.V. (QGEN): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research